Tributary Capital Management LLC Sells 155,806 Shares of Avanos Medical, Inc. (NYSE:AVNS)

Tributary Capital Management LLC lowered its holdings in Avanos Medical, Inc. (NYSE:AVNS - Free Report) by 17.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 737,202 shares of the company's stock after selling 155,806 shares during the period. Tributary Capital Management LLC owned approximately 1.60% of Avanos Medical worth $10,564,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. T. Rowe Price Investment Management Inc. increased its position in Avanos Medical by 27.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company's stock worth $47,941,000 after buying an additional 644,267 shares during the last quarter. Brown Advisory Inc. lifted its stake in shares of Avanos Medical by 12.0% in the fourth quarter. Brown Advisory Inc. now owns 1,905,094 shares of the company's stock valued at $30,329,000 after buying an additional 204,218 shares during the period. D. E. Shaw & Co. Inc. lifted its stake in shares of Avanos Medical by 43.1% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company's stock valued at $7,874,000 after buying an additional 148,902 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Avanos Medical by 189.8% in the fourth quarter. JPMorgan Chase & Co. now owns 201,634 shares of the company's stock valued at $3,210,000 after buying an additional 132,063 shares during the period. Finally, Bridgeway Capital Management LLC lifted its stake in shares of Avanos Medical by 87.6% in the fourth quarter. Bridgeway Capital Management LLC now owns 273,251 shares of the company's stock valued at $4,350,000 after buying an additional 127,591 shares during the period. Hedge funds and other institutional investors own 95.17% of the company's stock.

Avanos Medical Price Performance

AVNS traded down $0.39 during midday trading on Friday, reaching $11.25. 450,766 shares of the company's stock were exchanged, compared to its average volume of 392,004. The firm has a market capitalization of $520.25 million, a price-to-earnings ratio of -1.34 and a beta of 1.12. The company has a quick ratio of 1.56, a current ratio of 2.57 and a debt-to-equity ratio of 0.12. Avanos Medical, Inc. has a one year low of $11.21 and a one year high of $25.36. The business has a 50-day simple moving average of $12.32 and a two-hundred day simple moving average of $13.87.

Avanos Medical (NYSE:AVNS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.07. The company had revenue of $167.50 million during the quarter, compared to analyst estimates of $161.75 million. Avanos Medical had a negative net margin of 55.80% and a positive return on equity of 6.26%. The company's revenue was up .8% on a year-over-year basis. During the same quarter last year, the business posted $0.22 earnings per share. As a group, research analysts predict that Avanos Medical, Inc. will post 1.32 EPS for the current year.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.